Date: 2013-04-02
Type of information: Establishment of a new subsidiary in the EU
Compound:
Company: Bind Biosciences (USA - MA), now Bind Therapeutics (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: name change
Action mechanism:
Disease:
Details: * On April 2, 2013, Bind Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins™, announced that, effective immediately, it will begin operating as Bind Therapeutics to reflect the Company's progress in applying its Medicinal Nanoengineering® platform to develop a pipeline of highly selective targeted and programmable therapeutics called Accurins. The company's lead product candidate, BIND-014, has completed a Phase 1 clinical study in cancer patients. Bind Biosciences is initiating Phase 2 clinical trials in multiple solid tumor types.
Financial terms:
Latest news:
